Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...

Being exposed to bright light at night can significantly increase your chances of developing...

A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...

Content from other channels on our network

Grants to help NSW businesses reduce emissions

Specsavers partnership tackles optical waste

Concrete repair key to sustainability

Signposting the way to a regenerative economy

Pledges favour land-based carbon removal over emission cuts

Blending operations boosted using rotary batch mixer

CCEP inspires young workers to create influential change

Helen Strachan appointed Chair of Australian Grape & Wine

Boosting plant-based protein manufacturing in regional NSW

High-protein concepts on show in Paris

National concussion clinical guidelines now available

Eye care partnership looks to support First Nations optometrists

How are AI models approved for use in health care?

$910m new Rouse Hill Hospital — designs released

What is My Health Record? For healthcare providers